Core Insights - Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on cancer treatment through drug discovery and development [2][3] - The company will present an overview at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 [1] Company Overview - Cellectar's primary objective is to utilize its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to create next-generation cancer treatments with improved efficacy and safety [2] - The company is engaged in independent research and development as well as collaborations to enhance its drug pipeline [2] Product Pipeline - Key assets include: - Iopofosine I 131, a PDC for targeted delivery of iodine-131, currently in Phase 2b trials for multiple myeloma and CNS lymphoma [3][4] - CLR 121225, targeting solid tumors like pancreatic cancer using actinium-225 [3] - CLR 121125, aimed at other solid tumors such as triple negative breast cancer, lung cancer, and colorectal cancer [3] - The company has multiple partnered PDC assets and preclinical PDC chemotherapeutic programs [3] Regulatory Designations - Iopofosine I 131 has received six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations from the FDA for various cancer indications [4]
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference